Navigation Links
NASDAQ Gives Dynatronics a Second Six-Month Extension for Minimum Bid Price Compliance
Date:12/15/2010

SALT LAKE CITY, Dec. 15, 2010 /PRNewswire/ -- Dynatronics Corporation (Nasdaq: DYNT) today announced that NASDAQ has given the company until June 13, 2011, to comply with its $1 per share minimum bid rule.

"Given the challenges of the general economy, we welcome the grant by NASDAQ of an additional six months to cure the $1 minimum bid deficiency," stated Kelvyn H. Cullimore Jr., chairman and president of Dynatronics. "These difficult economic times have made it challenging for small public companies to maintain strength in their stock prices.  This extra time will provide an opportunity for the market to better understand the potential of some important new developments that we expect to announce over the coming weeks and months."

"Dynatronics' newly introduced e-commerce website is positively impacting sales and helping the company operate more efficiently.  In addition, we are working to capitalize on preferred vendor contracts signed over the past year as well as identify and introduce new products to the market," Cullimore added.

"Our preferred vendor contracts give us access to over 2,500 clinics that we are working to convert to our brand of products. This promises to be a source of increased revenue over the coming year as more clinics choose to purchase our devices and supplies," Cullimore continued. "We believe all of these improvements, together with the new initiatives being undertaken that we expect to disclose in the coming weeks and months, should continue to strengthen our business and build investor confidence in owning our stock."

Dynatronics manufactures, markets and distributes advanced-technology medical devices, orthopedic soft goods and supplies, treatment tables and rehabilitation equipment for the physical therapy, sports medicine, chiropractic, podiatry, plastic surgery, dermatology and other related medical, cosmetic and aesthetic markets. More information regarding Dynatronics is available at www.dynatronics.com.

This press release contains forward-looking statements. Those statements include references to the company's expectations and similar statements such as the statement regarding expectations for future announcements, increased revenue from preferred vendor contracts and continued strengthening in our business. Actual results may vary from the views expressed in the forward-looking statements contained in this release. The development and sale of the company's products are subject to a number of risks and uncertainties, including, but not limited to, changes in the regulatory environment, competitive factors, inventory risks due to shifts in market demand, market demand for the company's products, availability of financing at cost effective rates, and the risk factors listed from time to time in the company's SEC reports including, but not limited to, the report on Form 10-K for the year ended June 30, 2010.


'/>"/>
SOURCE Dynatronics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Nile Therapeutics Receives NASDAQ Notice; Will Request Hearing
2. Marshall Edwards Receives NASDAQ Notice Of Non-Compliance; Intends To Request Hearing
3. Penwest Pharmaceuticals Announces Intention to Terminate NASDAQ Listing and Registration
4. EntreMed Receives Notice of NASDAQ Compliance
5. Cyberonics Reports Inducement Equity Awards Under NASDAQ Listing Rule 5635(c)(4)
6. ThermoGenesis Regains Compliance With NASDAQ Listing Rules
7. Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
8. ThermoGenesis Announces Reverse Stock Split Effective on NASDAQ Capital Market August 27, 2010
9. Jiangbo Pharmaceuticals Chairman to Ring NASDAQ Opening Bell on August 27, 2010
10. EntreMed Receives NASDAQ Listing Rule 5550(b)(2) Determination Letter
11. Poniard Pharmaceuticals Receives NASDAQ Deficiency Notice Related to Minimum Bid Price
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... , Feb. 9, 2016  The Parenteral Drug ... professionals developing and manufacturing sterile drug products, today ... Regulatory Guidance Comparison – With link to Comparison ... issued by the U.S. FDA, the EU, the ... --> --> ...
(Date:2/8/2016)... , Feb.8, 2016 Alzheimer Diagnostic Tests ... Medical Devices sector report , "Alzheimer ... provides an overview of Alzheimer Diagnostic Tests currently ... information on the pipeline products with comparative analysis ... The report reviews major players involved in the ...
(Date:2/8/2016)... Cardiovascular Surgery Devices - Medical Devices Pipeline Assessment, ... report, "Cardiovascular Surgery Devices - Medical Devices Pipeline ... Devices currently in pipeline stage. ... comprehensive information on the pipeline products with comparative ... development. The report reviews major players involved in ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... 2016 , ... Ross A. Clevens, MD, FACS , ... a new addition to their growing practice. Beginning this month, Teresa Imperiale-Westerfield, a ... performing cosmetic procedures including injectables, fillers and laser treatments. A master ...
(Date:2/10/2016)... TN (PRWEB) , ... February 09, 2016 , ... ... to sports concussion, yet the cause of injury may be one of many ... two-day advanced PT Continuing Education Course , Mastering Rehab Solutions for ...
(Date:2/9/2016)... ... February 09, 2016 , ... Steven Douglas Associates is a ... Florida Event, an upscale fundraiser held in South Florida. The Inaugural What’s Your Taste ... This year the event will be held in a new, more causal format at ...
(Date:2/9/2016)... Worth, Texas (PRWEB) , ... February 09, 2016 ... ... and reconstruction firm helping businesses recover after a disaster, announced today the acquisition ... service companies in Hawaii. , “Investing in like-minded companies who excel ...
(Date:2/9/2016)... ... February 09, 2016 , ... URise Products ... newest mobility device, the StandUp Walker. Made entirely in the USA, the StandUp ... 50 years. , StandUp Walker’s novel patent-pending design offers 2-in-1 benefits of ...
Breaking Medicine News(10 mins):